Last month, it was announced that two new drugs were approved by the US Food and Drug Administration, for treatment of Parkinson’s disease (PD). Both drugs, Rytary™ and Duopa™, are updates to carbidopa/levodopa. They offer, respectively, a newer formulation and delivery method to reduce off-times for those with PD. In this Q&A, PDF speaks with Myra Hirschhorn, one of our trained Research Advocates, to understand the community reaction to the approvals. As part of the Parkinson’s Advocates in Research program, Myra has been trained in the drug development process, and educates her community about research.
On February 2, a group of future osteopathic doctors at the Liberty University College of Osteopathic Medicine (LUCOM) hosted Pancakes for Parkinson’s, a breakfast to raise awareness of PD and funds for PDF. The students, who make up the university’s chapter of the national Student Osteopathic Medical Association, welcomed 100 guests and raised $400. In this Q&A, Pranamya Mahankali, chapter leader, shares why the students got involved as PDF Champions, plus we link to a local news cast featuring the students’ efforts.